Department of Surgery, Emory university school of medicine, Atlanta, US

Tyrosine enzyme inhibitors (TKIs) are very effective at inducement remissions and deceleration down the progression of chronic granulocytic leukemia (CML) leading to a major reduction in morbidity and mortality. Most patients with CML should stay on TKIs indefinitely and lots of expertise resistance or intolerance to TKIs requiring a switch to a second-line TKI, third-line TKI or additional. the aim of this review is to look at the underlying factors and succeeding economic and quality of life burdens related to TKI failure. we have a tendency to discuss the definitions and rates of TKI failure in CML and also the extent to that mutations and non-adherence area unit related to TKI failure. we have a tendency to conjointly review the few studies that have examined economic and patient outcomes related to TKI failure and that we recommend avenues for future analysis examining the results of TKI failure.

Tyrosine kinase inhibitors; Chronic myeloid leukemia; Resistance; Burden

Catherine Abern. The Cost of Tyrosine Kinase Inhibitor Failure in Chronic Myeloid Leukemia Patients. Insights Journal of Surgery and Clinical Case Reports 2021.